Development of 99mTc-N4-NIM for Molecular Imaging of Tumor Hypoxia by Ali, Mohammad S. et al.
Hindawi Publishing Corporation
Journal of Biomedicine and Biotechnology
Volume 2012, Article ID 828139, 9 pages
doi:10.1155/2012/828139
Research Article
Developmentof 99mTc-N4-NIM for Molecular Imaging of
Tumor Hypoxia
Mohammad S. Ali,1 Fan-LinKong,1 AlexRollo,1 Richard Mendez,1 SaadyKohanim,1
DanielLeeSmith,2 andDavidJ. Yang1
1Department of Experimental Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
2Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
Correspondence should be addressed to Mohammad S. Ali, mohammad.ali@mdanderson.org
Received 31 January 2012; Revised 24 March 2012; Accepted 1 April 2012
Academic Editor: Yasuhisa Fujibayashi
Copyright © 2012 Mohammad S. Ali et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Thenitrogroupof2-nitroimidazole (NIM)entersthetumorcells andisbioreductively activated and ﬁxedinthe hypoxia cells. 1,4,
8,11-tetraazacyclotetradecane(N4)hasshowntobeastablechelatorfor
99mTc.Thepresentstudywasaimedtodevelop
99mTc-cyc-
lam-2-nitroimidazole (
99mTc-N4-NIM) for tumor hypoxia imaging. N4-NIM precursor was synthesized by reacting N4-oxalate
and1,3-dibromopropane-NIM,yielded14%(totalsynthesis).Celluptakeof
99mTc-N4-NIMand
99mTc-N4wasobtainedin13762
rat mammary tumor cells and mesothelioma cells in 6-well plates. Tissue distribution of
99mTc-N4-NIM was evaluated in breast-
tumor-bearingratsat0.5–4hrs.Tumoroxygentensionwasmeasuredusinganoxygenprobe.Planarimagingwasperformedinthe
tumor-bearingratandrabbitmodels.Radiochemicalpurityof
99mTc-N4-NIMwas>96%byHPLC.Celluptakeof
99mTc-N4-NIM
was higher than
99mTc-N4 in both cell lines. Biodistribution of
99mTc-N4-NIM showed increased tumor-to-blood and tumor-to-
muscle count density ratios as a function of time. Oxygen tension in tumor tissue was 6–10mmHg compared to 40–50mmHg in
normal muscletissue.Planar imaging studies conﬁrmed that the tumorscould bevisualized clearly with
99mTc-N4-NIM inanimal
models.EﬃcientsynthesisofN4-NIMwasachieved.
99mTc-N4-NIMisanovelhypoxicprobeandmaybeusefulinevaluatingcan-
cer therapy.
1.Introduction
Recent studies demonstrated that the hypoxic environment
induces more malignant neoplastic phenotypes [1]. Disrup-
tion of oxygen delivery to tumors could diminish apoptotic
potential and increase the chemotherapy/radiation resis-
tance, while an improvement in oxygen delivery to tumors
increases tumor sensitivity to radiation and chemotherapy
[2–4]. Due to its signiﬁcant prognostic and therapeutic
implication, eﬀorts have been made to invent eﬃcient non-
invasive methods to assess the presence and extent of tumor
hypoxia because information on the hypoxic fraction in
tumors could aid to reveal the mechanisms of aggressive
behavior. The success of the endeavor to noninvasively detect
the hypoxic fraction of tumor by nuclear molecular imag-
ing such as single-photon emission computed tomography
(SPECT) allows physicians to select patients for additional
or alternative treatment regimens that may circumvent or
overcome the ominous impact of tumor hypoxia and im-
prove disease control [5].
The nitro group of nitroimidazole is enzymatically redu-
ced by ribonucleoside reductase within viable hypoxic cells.
This mechanism is well understood through numerous in
vitro and in vivo studies from the past three decades [6].
In aerobic cells the reduced nitroimidazole is immediately
reoxidized and washed out rapidly. On the contrary, in cells
with low oxygen concentration the reoxidation is slowed,
which allows further reductive reactions to take place. This
leads to the formation of reactive products that could cov-
alently bind to cell components and thus diﬀuse more
slowly out of the tissue in an oxygen-dependent man-
ner [7]. 18F-Fluoromisonidazole (18F-FMISO) and 18F-ﬂuo-
roerythronitroimidazole (18F-FETNIM), 2-nitroimidazole
analogues, have been used with PET to evaluate tumor2 Journal of Biomedicine and Biotechnology
hypoxia, but the chemistries are dependent on a cyclotron
to produce 18F in addition to slow serum clearances [8–10].
In an attempt to identify eﬃcient and clinically user-
friendly chelator-based hypoxia tracers, our team has devel-
oped a new class of 99mTc hypoxia SPECT tracers based on
the nitroimidazole backbone. The nitrogen, oxygen, and sul-
fur combination has shown to be stable chelators for radio-
metals [11–18]. The chelator used in this paper is 1,4,8,11-
tetraazabicyclohexadecane (N4) which has shown to be a
stable chelator for 99mTc [11, 12]. In addition, N4-chemistry
could be easily modiﬁed and selectively reacted with halo-
genated homing compounds. In this paper, the potential
use of 99mTc-N4-NIM as tumor hypoxic imaging agent was
evaluated. The advantage of 99mTc-N4-nitroimidazole over
18F-FMISO and 18F-FETNIM is its easier chemistry and its
water solubility that may lead to the rapid clearance of un-
bounded tracers after intravenous injection.
2.MaterialsandMethods
2.1.ChemicalsandAnalysis. Allchemicalsofanalyticalgrade
and solvents of high performance liquid chromatography
(HPLC) grade were obtained from Sigma-Aldrich (St. Louis,
MO, USA). Nuclear magnetic resonance (NMR) was per-
formed on a Bruker 300-MHz spectrometer (Bruker BioSpin
Corporation, Billerica, MA, USA), and mass spectra were
performed on a Waters Q-TOF Ultima mass spectrometer
(Waters, Milford, MA, USA) at the chemistry core facility at
TheUniversityofTexasMDAndersonCancerCenter(Hous-
ton, TX, USA). Sodium pertechnetate (Na 99mTcO4)w a s
obtainedfroma 99Mo/99mTcgenerator(Covidien,Mansﬁeld,
MA, USA).
2.2.SodiumSaltof2-Nitroimidazole(Compound1). Thesyn-
thetic scheme of N4-NIM is shown in Figure 1. One molar
equivalent of NaOH 1M (0.3864g, 9.66mmol, 9.66mL) was
added to 2-nitroimidazole (1.09g, 9.66mmol) and warmed
30 minutes at 50◦C to dissolve it. If the compound was not
dissolvedinthesolutionthenNaOHwasaddeddropbydrop
until the solid was dissolved completely and we continue
heating for 15 minutes more. Water was removed on rotary
evaporator. Crude compound was dissolved in minimum
quantity of water, ﬁltered, and lyophilized. Yield: 5.31g,
(90%).
2.3. Bromopropane Nitroimidazole (Compound 2). In two-
neck ﬂask one molar equivalent of Sodium salt of 2-nitro-
imidazole (2.00g, 14.7mmol) in solid form was added in
40mL of acetonitrile (anhydrous) to dissolve it, then 18-
crown-6 (3.88g, 14.7mmol) was added to this mixture. In
nitrogen atmosphere 12.5 molar equivalent of 1,3-dibromo-
propane (18.65mL, 183.76mmol, 37.09g) was added to the
reaction mixture. The reaction mixture was then reﬂuxed in
a nitrogen environment at 50◦C overnight. The reaction was
ﬁltered to purify the precipitate of NaBr using the 0.22μM
ﬁlter paper. Soon after the solvent was evaporated, the crude
compound was puriﬁed by column chromatography with a
CHCl3 :CH 3OH mixture (v:v, 9:1). Yield: 10.45g (90%).
2.4.N1,N 4-Dioxylyl-1,4,8,11-Tetraazacyclotetradecane(Com-
pound 3). 1,4,8,11-Tetraazacyclotetradecance (N4) (2.997g,
14.974mmol)wasdissolvedin50mLofethanol(anhydrous)
ethanol, and after heating at 50◦C, diethyl oxalate (2.188g,
14.974mmol, 2.03mL) was added. The reaction mixture
w a sr e ﬂ u x e df o r1 8h o u r sa t7 5 ◦C. The solvent was rotary
evaporatedandthecrudeproductwasdissolvedinminimum
quantity of ethanol and the turbid solution was ﬁltered with
0.22μM ﬁlter. Crude compound was dissolved in minimum
amount of anhydrous ethanol and kept rotating on rotary
evaporator for 40 minutes at 40–50◦C. The compound was
crystallized by adding 200mL acetone (anhydrous) leaving
the solution overnight in the refrigerator to yield white crys-
tals of N1,N 4-dioxylyl-1,4,8,11-tetraazacyclotetradecane.
Yield: 8.64g (52.04%) Ms (m/z) 255.19 [M]+.
2.5. 1-[3-(2-Nitroimidazole-1-yl)propyl]-(N1,N4-Dioxylyl-1,
4,8,11-Tetraazacyclotetradecane) (Compound 4). N1,N4-
dioxylyl-1,4,8,11-tetraazacyclotetradecane (0.5746g, 2.259
mmol) was placed into the two-neck ﬂask and dissolved in
25mL of DMF (anhydrous). While heating the solution at
50◦C, bromonitroimidazole (0.5329g, 2.259mmol) dis-
solved in 2.0mL of DMF (anhydrous) was added to the
reactionmixture.AfteraddingK2CO3 (anhydrous)(0.7805g;
5.6475mmol) in 2.5 molar equivalent solid to the reaction
mixture, it was reﬂuxed at 70◦C overnight. Crude compound
was ﬁltered using 0.22μM ﬁlter paper and checked by TLC
in chloroform: methanol in an 8:2 solvent system. Solvent
w a st h e ne v a p o r a t e da n dc r u d ec o m p o u n dw a sp u r i ﬁ e d
by column chromatography in (8:2) of chloroform and
methanol. Yield: 6.96g, (75.86%). Ms (m/z) 408.30 [M]+.
2.6. 1-[3-(2-Nitroimidazole-1-yl)propyl]-(1,4,8,11-Tetraaza-
cyclotetradecane) (Compound 5, N4-NIM). To a 1 equiva-
lent solution of (N4OxaNIM) N1,N4-dioxylyl-1,4,8,11-tetra-
azacyclotetradecane (0.100g; 0.246mmol) in 1mL of water,
10equivalentsof10NNaOH(0.246mL)wereadded,stirred,
and reﬂuxed over night at 75◦C. The solvent was evaporated
under vacuum, giving oﬀ white solid. The crude compound
was dissolved in minimum quantity of water and ﬁltered,
then puriﬁed by sephadex G25 column. The fractions were
lyophilized and collected by checking 1HNMRasoﬀ white
solid. Yield: 0.045g (52.32%).
2.7. Radiolabeling of N4-NIM with 99mTc. Radiosynthesis of
99mTc-N4-NIM was achieved by adding a required amount
of 99mTc-pertechnetate into a kit containing the lyophilized
residue of N4-NIM (1mg) and SnCl2 (100μg). Final pH of
thepreparationwas5.5–7.4.Radiochemicalpuritywasdeter-
mined by TLC and HPLC. Radio-TLC (Waterman No. 1)
was obtained by eluting 99mTc-N4-NIM with acetone and
saline, respectively. Radio-HPLC (Waters) was obtained by
eluting 99mTc-N4-NIM on a C-18 reverse phase column
(4.5 × 250mm, 5μm diameter, Zorbax Extend C 18, Agilant
Technologies, Santa Clara, CA, USA) with 8:2 acetonitrile:
water solution (v:v) using a ﬂow rate of 0.5mL/minuteJournal of Biomedicine and Biotechnology 3
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Figure 1: Synthetic scheme of N4-NIM.
at UV 210 and 254nm. The concentration of 99mTc-N4-
NIMwas1.0mg/1.96mCi/500μLH 2O.Theconcentrationof
unlabeled N4-NIM was 1.7mg/200μLH 2O.
2.8.CellularUptakeof 99mTc-N4-NIM. The13762mammary
cancer cells and mesothelioma cells (IL-45) were plated to 6-
welltissuecultureplatesthatcontained2 ×105 cells/welland
incubated with 99mTc-N4-NIM (0.05mg/well, 8μCi/well)
and 99mTc-N4 (0.025mg/well, 8μCi/well) for 0–4 hours.
After incubation, cells were washed with ice-cold phosphate-
buﬀered solution twice and detached using a treatment of
0.5mLoftrypsinfor5minutes.Cellswerethencollectedand
the radioactivity of the cells was measured in triplicate with
a gamma counter. Radioactivity was expressed as mean ±
standard deviation percent of cellular uptake (%Uptake).4 Journal of Biomedicine and Biotechnology
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Figure 2: HPLC analysis of N4-NIM (left) and 99mTc-N4-NIM (right). The purity of both N4NIM and 99mTc-N4-NIM was 96%.
2.9. Biodistribution and Radiation Dosimetry Estimates of
99mTc-N4-NIM. The animal experiments were carried out
in compliance with the relevant national laws relating to
the conduct of animal experimentation. The animal protocol
was approved by The University of Texas M. D. Anderson
Cancer Center Animal Care and Use Committee (IACUC).
Female Fischer 344 rats (150 ± 25g) (Harlan Sprague-
Dawley, Indianapolis, IN) were inoculated subcutaneously
with 0.1mL of mammary tumor cells from the 13762 tumor
cell line suspension (106 cells/rat, a tumor cell line speciﬁc
to Fischer rats) into the hind legs using 25-gauge needles.
Studies were performed 14 to 17 days after implantation
when tumors reached approximately 1cm diameter. The rats
were divided into 3 groups and each rat was injected intra-
venously with 25 ± 0.5μCi of 99mTc-N4-NIM and 99mTc-N4.
Each group was examined at 1 of 3 time points (0.5, 2, or
4 hours after injection). At each time point, the rats were
killed and the selected tissues were excised, weighed, and
measured for radioactivity by gamma counter. For each
sample, radioactivity was expressed as mean percentage of
the injected dose per gram of tissue wet weight (%ID/g).
Counts from a 1/10 diluted sample of the original injection
were used as a reference.
Tumor/nontarget tissue count density ratios were calcu-
lated from the corresponding %ID/g values. Olinda software
(version 1.1; Vanderbilt University, Nashville, TN, USA) was
used to determine dosimetry, based upon preclinical source
organ residence time estimates as followed: rat organ distri-
bution data was processed using in-house software to deter-
mine residence times (τ) based on AUC. The data was then
converted to human residence time estimates using the cor-
rection factor for each organ, and subsequent τ values were
entered into Olinda software to generate human dose esti-
mates.
2.10. Polarographic pO2 Measurements of Mammary Tumors.
To conﬁrm tumor hypoxia, intratumoral pO2 measurementsJournal of Biomedicine and Biotechnology 5
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Figure 3: In vitro cell uptake studies using rat mammary cancer cells and mesothelioma cells revealed that 99mTc-N4-NIM had high uptake
in both cell lines.
were performed using the Eppendorf computerized histo-
graphic system. Twenty to twenty-ﬁve pO2 measurements
along each of two to three linear tracks were performed
at 0.4mm intervals on each tumor (40–75 measurements
total).TumorpO2 measurementsweremadeonthreetumor-
bearing rats. Using an on-line computer system, the pO2
measurements of each track were expressed as absolute
values relative to the location of the measuring point along
the track and as the relative frequencies within a pO2 histo-
grambetween0and100mmHgwithaclasswidthof2.5mm.
2.11. Planar Scintigraphic Imaging in Tumor-Bearing Models.
Two animal models were created. For Rabbit model, the
VX-2 tumor mass was inoculated (im) to the thigh region
of male New Zealand white rabbits (2kg). For rat model,
cells from the mammary tumor cell line 13762, suspended
in phosphate-buﬀered solution (105 cells/0.1mL solution
per rat), were injected subcutaneously into the right calf
muscle of female Fischer 344 rats. Planar scintigraphic
imaging of 99mTc-N4-NIM was performed 12–14 days after
inoculation when tumors reached approximately 1cm in
diameter. The animals were anesthetized and injected in-
travenously with 99mTc-N4-NIM (0.3mg/rat, 300μCi/rat;
1.5mCi/rabbit), and images were acquired at 30, 120, and
240 minutes after administration of tracers. Planar scinti-
graphic images were obtained using M-CAM (Siemens
Medical Solutions, Hoﬀman Estates, IL, USA) equipped with
alow-energy high-resolution collimator.Computer-outlined
regions of interest (ROIs in counts per pixel) between tumor
and muscle tissue were used to calculate tumor-to-muscle
(T/M) ratios. Percent of injected dose (%ID) in the tumor
was also calculated from the reference standard, which was
1/10 of the original injection activity of 99mTc-N4-NIM.
3. Results
3.1. Chemistry and Radiochemistry. The synthetic scheme is
shown in Figure 1. The total synthesis yield of precursor N4-
NIM via our 5-step procedure was 14%. The structure and
purity of N4-NIM were conﬁrmed by 1H- and 13C-NMR,
mass spectra, and HPLC. The N4-NIM 1H-NMR results
(D2O δ, ppm) were as follows: 8.25 (s, H, imidazole ring),
3.74 (s, H, imidazole ring), 3.17–3.25 (t, 2H,CH2 of propyl
group), 3.05–2.91 (t, 2H, CH2 of propyl group), 2.26–2.76
(m, 2H, CH2 of propyl group), 2.28–2.48 (m, 14H, CH2
of N4 ring), and 1.38–1.68 (m, 6H, CH2 of N4 ring).
13C-NMR results (D2O δ, ppm) were as follows: 180.27,
173.13,164.13,61.48,54.13,51.73,50.20,49.45,48.29,46.61,
24.64, 23.76, and 22.64. Ms (m/z) 377.24 [M]+. In radio-
TLC analysis, 99mTc-N4-NIM did not migrate either in
saline or acetone solvent. HPLC analysis showed that the
retention time for N4-NIM was 3.506min and 3.690min
at UV-254 and 210nm, respectively. N4-NIM was labeled
with 99mTc successfully with high radiochemical purity
(>96%)(Figure 2).HPLCanalysisshowedtheretentiontime
for 99mTc-N4-NIM was 3.663min (UV-254nm), 3.650min
(UV-210nm), and 4.200min (NaI detector). Because 99mTc-
N4-NIM is a kit product and labeled without any further
puriﬁcation, its radiochemical yield was assumed to be
identical to its radio-chemical purity.6 Journal of Biomedicine and Biotechnology
Table 1: Biodistribution of 99mTc-N4 in mammary tumor-bearing rats.
% of injected dose per gram of tissue weight
(n = 3/time, interval, iv)
30 min 120 min 240 min
Blood 0.23 ±0.009 0.04 ±0.002 0.02 ±0.002
Heart 0.07 ±0.005 0.01 ±0.001 0.01 ±0.000
Lung 0.20 ±0.011 0.05 ±0.002 0.03 ±0.001
Thyroid 0.25 ±0.011 0.03 ±0.002 0.02 ±0.001
Pancreas 0.07 ±0.007 0.02 ±0.002 0.02 ±0.001
Liver 2.98 ±0.083 1.14 ±0.018 0.79 ±0.026
Spleen 0.35 ±0.026 0.37 ±0.007 0.39 ±0.020
Kidney 2.56 ±0.101 1.11 ±0.045 0.65 ±0.028
Stomach 0.12 ±0.005 0.02 ±0.001 0.01 ±0.000
Intestine 0.25 ±0.004 0.39 ±0.048 0.14 ±0.003
Uterus 0.16 ±0.014 0.02 ±0.001 0.01 ±0.001
Tumor 0.09 ±0.004 0.03 ±0.003 0.02 ±0.001
Muscle 0.05 ±0.002 0.01 ±0.000 0.01 ±0.000
Bone 0.07 ±0.001 0.02 ±0.001 0.01 ±0.000
Brain 0.01 ±0.000 0.00 ±0.000 0.00 ±0.000
Tumor/blood 0.40 ±0.002 0.78 ±0.044 0.70 ±0.008
Tumor/muscle 1.96 ±0.015 5.32 ±0.402 3.35 ±0.147
Tumor/brain 6.19 ±0.365 11.06 ±0.667 11.93 ±0.675
Value shown represents the mean ± standard deviation of data from 3 animals.
3.2. In Vitro Cellular Uptake Assays. The cellular uptake
kinetics of 99mTc-N4-NIM and 99mTc-N4 in rat mammary
tumorcellsandratmesotheliomacellsareshowninFigure 3.
The uptake for 99mTc-N4-NIM increased dramatically up
to 240 minutes, but this was not the case for the 99mTc-
N4, suggesting that 99mTc-N4-NIM can enter tumor cells
speciﬁcally and accumulate rapidly.
3.3. Biodistribution and Radiation Dosimetry Estimates of
99mTc-N4-NIM. Tissuedistributionof 99mTc-N4and 99mTc-
N4-NIM is shown in Tables 1 and 2. Biodistribution studies
showed that tumor/blood and tumor/muscle count density
ratios at 0.5–4hr gradually increased for 99mTc-N4-NIM
(Table 2). No signiﬁcant uptake in thyroid and stomach
suggests in vivo stability of 99mTc-N4-NIM. The optimal
tumor imaging time for 99mTc-N4-NIM is at 2hr post-
administration of 99mTc-N4-NIM. Although tumor/blood
and tumor/muscle count density ratios at 0.5–4hr gradually
increased for 99mTc-N4, yet there was almost no tumor up-
take (Table 1). Based upon preclinical studies, dosimetry of
99mTc-N4-NIM was estimated from MIRDose. It is safe to
use 99mTc-N4-NIM in human because the whole body, liver,
and eﬀective dose equivalent for the proposed single dose at
20 mCi of 99mTc-N4-NIM were less than the limits for 3rem
annual and 5rem total dose equivalent, and other organs
of single dose at 5rem annual and total dose equivalent
at 15rem if the subject did not have any other radiation
exposure (Table 3).
Table 2: Biodistribution of 99mTc-N4-NIM in mammary tumor-
bearing rats.
% of injected dose per gram of tissue weight
(n = 3/time, interval, iv)
30min 2h 4h
Blood 0.76 ±0.06 0.20 ±0.01 0.16 ±0.01
Heart 0.26 ±0.03 0.07 ±0.01 0.04 ±0.00
Lung 0.58 ±0.06 0.17 ±0.00 0.10 ±0.00
Thyroid 0.71 ±0.06 0.17 ±0.01 0.08 ±0.00
Pancreas 0.22 ±0.03 0.06 ±0.00 0.04 ±0.01
Liver 0.88 ±0.05 0.84 ±0.03 0.51 ±0.02
Spleen 0.74 ±0.13 0.42 ±0.01 0.70 ±0.02
Kidney 4.92 ±0.89 4.42 ±0.06 1.33 ±0.10
Stomach 0.37 ±0.04 0.09 ±0.01 0.03 ±0.00
Intestine 0.33 ±0.04 0.15 ±0.07 0.04 ±0.01
Uterus 0.61 ±0.16 0.20 ±0.11 0.08 ±0.01
Tumor 0.52 ±0.02 0.20 ±0.00 0.08 ±0.00
Muscle 0.18 ±0.01 0.04 ±0.00 0.02 ±0.00
Bone 0.22 ±0.08 0.14 ±0.02 0.03 ±0.00
Brain 0.04 ±0.00 0.01 ±0.00 0.01 ±0.00
Tumor/blood 0.69 ±0.02 1.01 ±0.05 0.98 ±0.06
Tumor/muscle 2.86 ±0.19 5.69 ±0.40 4.88 ±0.56
Tumor/brain 12.74±2.26 15.51±2.16 15.10±2.47
Values shown represent the mean ± standard deviation of data from 3
animals.Journal of Biomedicine and Biotechnology 7
Table 3: Radiation dose estimates for the reference adult for 99mTc-
N4-NIM.
Target organ rad/mCi Human dose
(mCi) rad
Organs (5 rem annual/15 rem total)
Adrenals 6.56E −03 20 0.131
Brain 5.03E −04 20 0.010
Breasts 1.22E −03 20 0.024
Gall bladder wall 4.28E −03 20 0.086
Lli wall 1.53E −03 20 0.031
Small int 2.97E −03 20 0.059
Stomach 4.19E −03 20 0.084
Uli wall 2.74E −03 20 0.055
Heart wall 5.50E −03 20 0.110
Kidneys 8.20E −02 20 1.640
Liver 4.41E −03 20 0.088
Lungs 5.05E −03 20 0.101
Muscle 1.46E −03 20 0.029
Pancreas 8.44E −03 20 0.169
Bone surfaces 4.11E −03 20 0.082
Skin 8.81E −04 20 0.018
Testes 8.11E −04 20 0.016
Thymus 1.69E −03 20 0.034
Thyroid 9.93E −04 20 0.020
Urine bladder wall 1.18E −03 20 0.024
Uterus 1.65E −03 20 0.033
Eﬀ dose 3.41E −03 20 0.068
Blood-forming organs (3 rem annual/5 rem total)
Ovaries 1.67E −03 20 0.033
Red marrow 2.15E −03 20 0.043
Spleen 3.27E −02 20 0.654
Eﬀ dose eq 9.73E −03 20 0.195
Total body 2.26E −03 20 0.045
3.4. Polarographic Oxygen Microelectrode pO2 Measurements.
Intratumoral pO2 measurements of mammary tumors indi-
cated the tumor oxygen tension ranged 4.6 ± 1.4mmHg as
compared to normal muscle of 35 ± 10mmHg. The data
indicated that the tumors were hypoxic.
3.5. Planar Scintigraphic Imaging in Tumor-Bearing Models.
The selected planar scintigraphic images of tumor-bearing
rats and rabbits after 99mTc-N4-NIM injection are shown in
Figures 4 and 5. Tumors could be clearly detected by 99mTc-
N4-NIM. The T/M ratios at 60–120 minutes were 4.1–4.2 in
tumor-bearing rats and 2.52–2.98 in tumor-bearing rabbits,
respectively.
4. Discussion
The development of new tumor hypoxia agents is clinically
desirable for detecting primary and metastatic lesions as well
as predicting radioresponsiveness and time to recurrence
[10, 19]. None of the contemporary imaging modalities
accurately measures hypoxia since the diagnosis of tumor
hypoxia requires a pathologic examination. It is often diﬃ-
cult to predict the outcome of a therapy for hypoxic tumor
without knowing at least the baseline of hypoxia in each
tumor treated. Although the Eppendorf polarographic oxy-
gen microelectrode can measure the oxygen tension in a
tumor,thistechniqueisinvasiveandneedsaskillfuloperator.
Additionally, this technique can only be used on accessible
tumors (e.g., head and neck, cervical) and multiple readings
are needed. Therefore, an accurate and easy method of
measuring tumor hypoxia will be useful for patient selection.
However, tumor-to-normal tissue uptake ratios vary and
depend upon the radiopharmaceuticals used. Therefore, it
wouldberationaltocorrelatetumor-to-normaltissueuptake
ratios with the gold standard Eppendorf electrode measures
of hypoxia when new radiopharmaceuticals are introduced
to clinical practice.
In biodistribution, 99mTc-N4-NIM in tumor tissue was
decreased as same as 99mTc-N4 (Tables 1 and 2). This dec-
reased uptake might be due to slower uptake 99mTc-N4 and
99mTc-N4-NIM as a function of increased renal excretion.
However, the tumor uptake as well as tumor/blood and
tumor/muscleratiosin 99mTc-N4-NIMwerehigherthanthat
in 99mTc-N4 group.
Hypoxia-Inducible Factor (HIF)-1α/β heterodimer is a
master transcription factor for several genes involved in
angiogenesis, glycolysis, pH balance, and metastasis. These
HIF-1 target genes help tumors to overcome forthcoming
metabolicobstaclesastheygrow.Undernormoxiccondition,
the HIF-1α subunit is hydroxylated by its speciﬁc prolyl-
4 hydroxylase 2, given the acronym PHD2, thus stabilizing
it under normoxic conditions [20]. In vitro cellular uptake
assay, the uptake of 99mTc-N4-NIM in tumor cells increases
upto240min.However,thisassaywasperformedundernor-
moxic condition. The increased uptake of 99mTc-N4-NIM
intumorcellsundernormoxicconditionmightbeduetosta-
bilized HIF-1α.N a T c O 4 was reduced to +5Tc [O] and bound
to the three nitrogens of cyclam. The charge of 99mTc-
N4-NIM is neutral. Cell uptake of 99mTc-N4-NIM was via
passive diﬀusion.
In our animal model, tumor oxygen tension was deter-
mined to be 3.2 to 6.0mmHg, whereas normal muscle tissue
had30to40mmHg.Althoughanotherfactorsuchasanemia
may have inﬂuenced the level of tumorhypoxia, there was no
attempt in identifying this factor. In biodistribution, 99mTc-
N4-NIM in tumor tissue was decreased as same as 99mTc-
N4 (Tables 1 and 2). This decreased uptake might be due to
sloweruptakeof 99mTc-N4and 99mTc-N4-NIMasafunction
of increased renal excretion. However, the tumor uptake as
well as tumor/blood and tumor/muscle ratios in 99mTc-N4-
NIM was higher than those in 99mTc-N4 group.
Due to better imaging characteristics and lower cost,
attempts are made to replace the 123I-, 131I-, 67Ga-, and 111In-
labeled compounds with corresponding 99mTc-labeled com-
pounds when possible. Our radiochemistry data indicated
N4-NIM could be labeled with 99mTc very easily and eﬃ-
ciently at room temperature with high radiochemical purity.8 Journal of Biomedicine and Biotechnology
60min 120min
99mTc-N4
T/M = 3.15 T/M = 3.1
(a)
60min 120min
99mTc-N4-NIM
T/M = 4.2 T/M = 4.1
(b)
Figure 4: Planar scintigraphy of 99mTc-N4 and 99mTc-N4-NIM (400μCi/rat, iv, acquired 500,000 count) showed higher tumor-to-muscle
count density ratio in 99mTc-N4-NIM compared to that of 99mTc-N4. The numbers are tumor-to-muscle count density ratios (counts/pixel)
at 60–120min.
60min
T
T/M = 2.92
(a)
T
120min
T/M = 2.58
(b)
Figure 5: Planar scintigraphy of 99mTc-N4-NIM (15 mCi/rabbit, iv, acquired 500,000 count) showed higher tumor-to-muscle count density
ratio (counts/pixel) at 60 and 120min.
In vivo tissue distribution studies showed that radiation
dosimetry of blood-forming organs was within radiation
dose limits. Our planar imaging studies indicate that 99mTc-
N4-NIM is feasible to assess tumor hypoxia.
In summary, N4-NIM kits could be labeled with
99mTc easily and eﬃciently, with high radiochemical purity
and cost-eﬀectiveness. In vitro cellular uptake and scinti-
graphic imaging studies demonstrated the pharmacokinetic
distribution and feasibility of using 99mTc-N4-NIM for
tumor hypoxia imaging.
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